Gut flora and synbiotics therapy in patients with severe SIRS

严重 SIRS 患者的肠道菌群和合生元治疗

• 批准号: 17591887
• 负责人: SHIMIZU Kentaro
• 金额: $ 2.3万
• 依托单位: Osaka University
• 依托单位国家: 日本
• 项目类别: Grant-in-Aid for Scientific Research (C)
• 财政年份: 2005
• 资助国家: 日本
• 起止时间: 2005 至 2007
• 项目状态: 已结题
• 来源: https://kaken.nii.ac.jp/grant/KAKENHI-PROJECT-17591887/
• 关键词: Synbiotics; Systemic inflammatory response syndrome; gut; sepsis; short-chain fatty acids; probiotics; prebiotics; flora; 腸内細菌叢; pH; SIRS

The gut is considered an important target organ of injury following severe insult such as sepsis, trauma, and shock. Synbiotics therapy is a combination with probiotics and prebiotics. We quantitatively evaluated changes in the gut microflora and environment in patients with severe SIRS, examined the effects of synbiotic treatment on clinical course, and evaluated the limitation of synbiotic treatment on gut dysmotility.1) The gut flora and environment are significantly altered in patients with severe SIRS. Analysis of fecal flora confirmed that patients with severe SIRS showed significantly lower total anaerobic bacterial counts, in particular, 2-4 log units fewer beneficial Bifidobacterium and Lactobacillus and 2 log units more pathogenic Staphylococcus and Pseudomonas group counts than did healthy volunteers. Concentrations of total fecal organic acids, in particular, beneficial short-chain fatty acids such as acetic acid, propionic acid, and butyric acid, were significantly decreas … More ed in the patients.2) Synbiotics maintain the gut flora and environment in patients with severe SIRS and significantly reduce the incidence of septic complications. The incidences of infectious complications in patients with severe SIRS were significantly lower in the synbiotics group than in the control group(enteritis, 7%vs. 46%, pneumonia, 20% vs. 52%,and bacteremia, 10%vs. 33%, respectively). These beneficial effects of synbiotics in the present study may be due to improved gut flora, increased short-chain fatty acids.3) In SIRS patients with synbiotic therapy(50cases), intestinal dymotility patients(5 cases) all had deterioration in their gut flora, caused bacteremia, and were mortal.As a result, the deterioration of gut flora were related with septic complications and mortality. Synbiotics could maintain the gut flora and protect the critically ill patients from infectious complications. Further study is needed to clarify the mechanisms by which synbiotics decrease septic complications in patients with SIRS. Less

肠道被认为是脓毒症、创伤和休克等严重伤害后的重要损伤靶器官。合生元治疗是益生菌和益生元的结合。我们定量评估了重症SIRS患者肠道菌群和肠道环境的变化，观察了合生素治疗对临床病程的影响，并评价了合生素治疗对肠道动力障碍的限制1)重症SIRS患者的肠道菌群和环境明显改变。粪便菌群分析证实，重度SIRS患者的厌氧菌总数明显低于健康志愿者，尤其是有益双歧杆菌和乳杆菌减少2-4个对数单位，致病葡萄球菌和假单胞菌增加2个对数单位。粪便总有机酸的浓度，特别是有益的短链脂肪酸，如醋酸、丙酸和丁酸，显著降低了…2)合生元维持严重SIRS患者的肠道菌群和环境，显著降低败血症并发症的发生率。重症SIRS患者感染并发症发生率合生素组明显低于对照组(肠炎分别为7%和46%，肺炎分别为20%和52%，菌血症分别为10%和33%)。合生素的这些有益作用可能是通过改善肠道菌群，增加短链脂肪酸。3)在接受合生素治疗的SIRS患者(50例)中，肠动力障碍患者(5例)都有肠道菌群恶化，导致菌血症，并死亡。因此，肠道菌群的恶化与败血症的并发症和死亡率有关。合生元可以维持肠道菌群，保护危重患者免受感染并发症的侵袭。需要进一步研究阐明合生元降低全身炎症反应综合征患者败血症并发症的机制。较少

项目成果

SIRS患者における腸内細菌叢、腸内環境の変化とシンバイオティクス療法の有効性

SIRS 患者的肠道菌群、肠道环境变化以及合生元治疗的有效性

• 发表时间: 2006
• 期刊: 日本救急医学会雑誌 17巻12号
• 作者: 清水健太郎;小倉裕司;後藤美紀;朝原崇;野本康二;諸富正己;平出敦;松嶋麻子;田崎修;鍬方安行;田中裕;嶋津岳士;杉本壽
• 通讯作者: 杉本壽

熱傷患者の腸内細菌叢の変化と臨床経過〜3例の報告

烧伤患者肠道菌群变化及临床病程3例报告

• 发表时间: 2007
• 作者: Shimizu K;Ogura H;Goto M;Asahara T;Nomoto K;Morotomi M;Yoshiya K;Matsushima A;Sumi Y;Kuwagala Y;Tanaka H;Shimazu T;Sugimoto H.;清水健太郎;清水 健太郎;清水健太郎;清水健太郎;清水健太郎;清水健太郎;清水健太郎
• 通讯作者: 清水健太郎

SIRS患者における腸内細菌叢および腸内環境の崩壊とシンバイオティクス治療の効果

SIRS患者肠道菌群和肠道环境的破坏及合生元治疗的效果

• 发表时间: 2005
• 作者: Shimizu K. Ogura H;Goto M;Asahara T;Nomoto K;Morotomi M;Tasaki O;Kuwagata Y;Tanaka H;Shimazu T;Sugimoto H;清水健太郎
• 通讯作者: 清水健太郎

Intestinal dysmotility and enteritis increase septic mortality in patients with severe SIRS

肠动力障碍和肠炎会增加严重 SIRS 患者的败血症死亡率

• 发表时间: 2007
• 作者: Shimizu K;Ogura H;Goto M;Asahara T;Nomoto K;Morotomi M;Yoshiya K;Matsushima A;Sumi Y;Kuwagala Y;Tanaka H;Shimazu T;Sugimoto H.;清水健太郎;清水 健太郎;清水健太郎;清水健太郎;清水健太郎;清水健太郎;清水健太郎;清水健太郎
• 通讯作者: 清水健太郎

Synbiotics-感染制御のための新たな腸管内治療-

合生元 - 一种控制感染的新型肠道治疗方法 -

• 发表时间: 2006
• 作者: Shimizu K;Ogura H;Goto M;Asahara T;Nomoto K;Morotomi M;Tasaki O;Kuwagata Y;Tanaka H;Shimazu T;Sugimoto H;清水健太郎
• 通讯作者: 清水健太郎